BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 25546157)

  • 1. RET fusion as a novel driver of medullary thyroid carcinoma.
    Grubbs EG; Ng PK; Bui J; Busaidy NL; Chen K; Lee JE; Lu X; Lu H; Meric-Bernstam F; Mills GB; Palmer G; Perrier ND; Scott KL; Shaw KR; Waguespack SG; Williams MD; Yelensky R; Cote GJ
    J Clin Endocrinol Metab; 2015 Mar; 100(3):788-93. PubMed ID: 25546157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer.
    Ji JH; Oh YL; Hong M; Yun JW; Lee HW; Kim D; Ji Y; Kim DH; Park WY; Shin HT; Kim KM; Ahn MJ; Park K; Sun JM
    PLoS Genet; 2015 Aug; 11(8):e1005467. PubMed ID: 26295973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retroposed copies of RET gene: a somatically acquired event in medullary thyroid carcinoma.
    Bim LV; Navarro FCP; Valente FOF; Lima-Junior JV; Delcelo R; Dias-da-Silva MR; Maciel RMB; Galante PAF; Cerutti JM
    BMC Med Genomics; 2019 Jul; 12(1):104. PubMed ID: 31288802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
    Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.
    Moura MM; Cavaco BM; Pinto AE; Leite V
    J Clin Endocrinol Metab; 2011 May; 96(5):E863-8. PubMed ID: 21325462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sporadic minute medullary thyroid carcinoma with a double RET mutation: A case report.
    Yamamoto H; Ishii J; Chiba T; Nakazato Y; Hirano K; Kamma H
    Pathol Int; 2017 Nov; 67(11):580-584. PubMed ID: 28952196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medullary Thyroid Carcinoma: Recent Advances Including MicroRNA Expression.
    Chu YH; Lloyd RV
    Endocr Pathol; 2016 Dec; 27(4):312-324. PubMed ID: 27539727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
    Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
    Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prevalence of somatic RAS mutations in medullary thyroid cancer - a Polish population study.
    Oczko-Wojciechowska M; Pfeifer A; Rusinek D; Pawlaczek A; Zebracka-Gala J; Kowalska M; Kowal M; Swierniak M; Krajewska J; Gawlik T; Chmielik E; Czarniecka A; Szpak-Ulczok S; Jarząb B
    Endokrynol Pol; 2015; 66(2):121-5. PubMed ID: 25931041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic effect of oncogenic RET and loss of p18 on medullary thyroid carcinoma development.
    van Veelen W; van Gasteren CJ; Acton DS; Franklin DS; Berger R; Lips CJ; Höppener JW
    Cancer Res; 2008 Mar; 68(5):1329-37. PubMed ID: 18316595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions.
    Vanden Borre P; Schrock AB; Anderson PM; Morris JC; Heilmann AM; Holmes O; Wang K; Johnson A; Waguespack SG; Ou SI; Khan S; Fung KM; Stephens PJ; Erlich RL; Miller VA; Ross JS; Ali SM
    Oncologist; 2017 Mar; 22(3):255-263. PubMed ID: 28209747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of RET mutations on the expression of tyrosine kinases in medullary thyroid carcinoma.
    Rodríguez-Antona C; Muñoz-Repeto I; Inglada-Pérez L; de Cubas AA; Mancikova V; Cañamero M; Maliszewska A; Gómez A; Letón R; Leandro-García LJ; Comino-Méndez I; Sanchez L; Alvarez-Escolá C; Aller J; Cascón A; Robledo M
    Endocr Relat Cancer; 2013 Aug; 20(4):611-9. PubMed ID: 23780998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAS proto-oncogene in medullary thyroid carcinoma.
    Moura MM; Cavaco BM; Leite V
    Endocr Relat Cancer; 2015 Oct; 22(5):R235-52. PubMed ID: 26285815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of inherited genetic variants in ret proto-oncogene of Brazilian patients with apparently sporadic medullary thyroid carcinoma.
    Guerrero IM; Pessoa CH; Olmedo DB; Pontes ER; Matos LC; Tilli TM; Barcinski MA; Gimba ER
    Thyroid; 2006 Jan; 16(1):9-15. PubMed ID: 16487008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional characterization of the MTC-associated germline RET-K666E mutation: evidence of oncogenic potential enhanced by the G691S polymorphism.
    Borrello MG; Aiello A; Peissel B; Rizzetti MG; Mondellini P; Degl'Innocenti D; Catalano V; Gobbo M; Collini P; Bongarzone I; Pierotti MA; Greco A; Seregni E
    Endocr Relat Cancer; 2011 Aug; 18(4):519-27. PubMed ID: 21690267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma.
    Romei C; Ciampi R; Elisei R
    Nat Rev Endocrinol; 2016 Apr; 12(4):192-202. PubMed ID: 26868437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High prevalence of exon 8 G533C mutation in apparently sporadic medullary thyroid carcinoma in Greece.
    Sarika HL; Papathoma A; Garofalaki M; Vasileiou V; Vlassopoulou B; Anastasiou E; Alevizaki M
    Clin Endocrinol (Oxf); 2012 Dec; 77(6):857-62. PubMed ID: 22676047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular mechanisms underlying oncogenic RET fusion in lung adenocarcinoma.
    Mizukami T; Shiraishi K; Shimada Y; Ogiwara H; Tsuta K; Ichikawa H; Sakamoto H; Kato M; Shibata T; Nakano T; Kohno T
    J Thorac Oncol; 2014 May; 9(5):622-30. PubMed ID: 24722152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RET Copy Number Alteration in Medullary Thyroid Cancer Is a Rare Event Correlated with RET Somatic Mutations and High Allelic Frequency.
    Ramone T; Mulè C; Ciampi R; Bottici V; Cappagli V; Prete A; Matrone A; Piaggi P; Torregrossa L; Basolo F; Elisei R; Romei C
    Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33383911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
    Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
    Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.